14.3 C
New York
Tuesday, March 21, 2023

ResMed Inc. (RMD): A Case For Going Higher

After Hours

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for ResMed Inc. (RMD) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.36, or -0.16%, to $218.80. The ResMed Inc. has recorded 12,516 volume in the after hours trading session. Yahoo Finance discussed the stock recently as it posted ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2023.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


Stocks Info

The company is listed on the NYSE and operates within the Medical Instruments & Supplies industry segment. At the end of the last regular session, the stock closed at $219.16 and fluctuated between $220.67 as its day high and $218.09 as its day low. The current market capitalization of ResMed Inc. is $31.59B. A total of 0.62 million shares were traded on the day, compared to an average of 640.54K shares.

Insider Activity

Furthermore, investors take into consideration insider trades when predicting a stock’s future trajectory. During the recent three months, RMD has seen 2 BUY and 6 SELL insider trades, representing the acquisition of 11,350 and the disposition of 16,444 shares. Over the last 12 months, there were 48 BUYs and 62 SELLs from insiders. Insiders purchased 334,926 shares during that period but sold 264,843.

In the most recent transaction, Sandercock Brett sold 10,000 shares of RMD for 215.22 per share on Feb 17. After the transaction, the Chief Financial Officer now owns 106,880 company shares. In a previous transaction on Feb 15, Farrell Michael J. sold 5,675 shares at 214.83 per share. RMD shares that Chief Executive Officer owns now total 436,900.

Among the insiders who sold shares, Douglas Robert Andrew disposed of 1,500 shares on Feb 15 at a per-share price of $213.50. This resulted in the President and COO holding 261,445 shares of RMD after the transaction. In another insider transaction, Sandercock Brett sold 4,000 shares at $215.00 per share on Feb 13. Company shares held by the Chief Financial Officer now total 116,880.


The dividend paying company demonstrates a positive outlook for investors and helps them generate immediate cash. ResMed Inc. pays an annual dividend of $1.76, resulting in a dividend yield of 0.80%, and it has a price to earnings (P/E) ratio of 39.84. RMD’s most recent ex-dividend date was 2/8/2023 when it declared a $0.44 quarterly dividend that was paid in cash on 3/16/2023. Previously, the company paid the dividend on 12/15/2022 with an ex-dividend date of 11/9/2022. The RMD stock dividend was $0.44 per share in cash.

It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. According to analysts who have offered 12-month price targets for RMD in the last 3 months, the mean price target is $257.97 with high estimates of $280.00 and low estimates of $218.45. In terms of 52-week highs and lows, RMD has a high of $262.38 and a low of $189.40.

As of this writing, RMD has an earnings estimate of $1.6 per share for the current quarter. EPS was calculated based on a consensus of 8 estimates, with a high estimate of $1.72 per share and a lower estimate of $1.53. The company reported an EPS of $1.51 in the last quarter, which was -0.70% lower than expectations of $1.52.

Balance Sheet Annually/Quarterly

An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information.

Analysts Opinion

There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 22 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for RMD is Sell with a score of 4.33. A total of 12 analysts rated the stock as Buy while 4 rated it as Overweight while 6 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles